Clinical trials
Phase 1/2 randomized trial evaluating Allocetra™ intra-articular injection for the treatment of knee osteoarthritis
A double blind, randomized, multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra™ compared to placebo in patients with symptomatic knee osteoarthritis.
Learn moreAllocetra™ intra-articular injection for the treatment of end stage knee osteoarthritis
An investigator-initiated study to evaluate the safety and responses to intra-articular administration of Allocetra™ in patients with end-stage knee osteoarthritis.
Learn morePhase 1/2a randomized trial evaluating Allocetra™ intra-articular injection for the treatment of basal thumb joint (1st carpometacarpal joint) osteoarthritis
A double blind, randomized, investigator-initiated study to evaluate the safety and efficacy of intra-articular administration of Allocetra™ compared to placebo in patients with basal thumb joint (1st carpometacarpal joint) osteoarthritis.
Learn moreAllocetra™ intra-articular injection for the treatment of psoriatic arthritis
A phase 1 study to evaluate the safety and responses to intra-articular administration of Allocetra™ in patients with psoriatic arthritis.
Learn morePhase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
This is a pilot study to assess safety and possible efficacy of Allocetra-OTS in end-stage knee osteoarthritis.
Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
This is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous (IV) Allocetra-OTS 10x10^9 cells vs placebo (1:1) in adult hospitalized patients with severe or critical Coronavirus Disease 2019 (COVID-19) with associated acute respiratory distress syndrome (ARDS). Patients will be followed for efficacy and safety for 6 months. The trial will include periodic and ad-hoc DSMB review during the study period.